Clinical trials: in Moldova
Ischemic Stroke
A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA
This study will test the experimental drug "THR-18" given together with the drug "tissue plasminogen activator" for the treatment of stroke. Tissue plasminogen activator is also called "tPA".
- Trial name
- NCT02572336
- Testing
- THR-18, Tissue Plasminogen Activator (tPA)
- Where
- Moldova
- Volunteers
- 40 people
- Sponsor
- D-Pharm Ltd.
Rheumatoid Arthritis
A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
The main purpose of this study is to evaluate the safety of the study drug known as LY3090106 in healthy participants and in participants with RA who are having an inadequate response to methotrexate (MTX).
- Trial name
- NCT01925157
- Testing
- LY3090106 - SQ, LY3090106 - IV
- Where
- 4 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis
A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the treatment group.
- Trial name
- NCT02141763
- Testing
- UCB4940 40 mg, UCB4940 80 mg, UCB4940 160 mg
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 53 people
- Sponsor
- UCB Celltech
Pneumonia
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients
The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures used for diagnosis in daily routine…
- Trial name
- NCT00987792
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 11 sites in Croatia, France and 9 more
- Volunteers
- 2,595 people
- Sponsor
- Bayer
Inflammatory Arthritis
Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis
The main purpose of this study is to learn more about the safety of LY3114062 and to find out how well it is tolerated in participants with an inflammatory arthritis.
- Trial name
- NCT02144272
- Testing
- LY3114062 SC, LY3114062 IV
- Where
- 4 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the impact of JNJ-38518168 on rheumatoid arthritis (RA) disease-related biomarkers in synovial biopsy tissue and blood in participants with active RA despite methotrexate (MTX) therapy and…
- Trial name
- NCT01862224
- Testing
- JNJ-38518168, Methotrexate
- Where
- 2 sites in United States, Moldova
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in…
- Trial name
- DEFINE (NCT00420212)
- Testing
- BG00012
- Where
- 159 sites in United States, Australia and 27 more
- Volunteers
- 1,234 people
- Sponsor
- Biogen
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Pharmacokinetics of MDV3100, Healthy Subjects
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
This study will assess the influence of hepatic impairment on the pharmacokinetics, safety and tolerability of a single dose of MDV3100 in male subjects. The study will consist of two treatment arms.
- Conditions
- Pharmacokinetics of MDV3100, Healthy Subjects, Kidney Diseases
- Trial name
- NCT01901133
- Testing
- MDV3100
- Where
- Moldova
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Chronic Postoperative Pain
euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT Study
This project a European observational study on the incidence and characteristics of chronic post surgical pain (CPSP). Research Questions What is the incidence of chronic post surgical pain (CPSP) in Europe? What are the risk…
- Trial name
- PAIN-OUT (NCT01467102)
- Where
- 24 sites in Belgium, France and 9 more
- Volunteers
- 3,618 people, healthy volunteers welcome
- Sponsor
- European Society of Anaesthesiology
Tuberculosis, Tuberculosis, Multidrug-Resistant
Global Consortium for Drug-resistant Tuberculosis Diagnostics
The goal of this study is to evaluate time to diagnosis for three assays (line probe, pyrosequencing, and Microscopic Observation Drug Susceptibility Assay [MODS]) to detect resistance to first and second-line anti-tuberculosis…
- Trial name
- GCDD (NCT02170441)
- Where
- 3 sites in India, Moldova and 1 more
- Volunteers
- 1,128 people
- Sponsor
- University of California, San Diego
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Abortion, Induced
Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))
The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion.
- Trial name
- NCT00969982
- Testing
- mifepristone+misoprostol
- Where
- 2 sites in Moldova, Tunisia
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Induced Abortion
Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation
This open-label, randomized study is being conducted to determine whether a dose of 400 mcg of sublingual misoprostol (i.e., under the tongue) taken 24 hours following administration of mifepristone 200 mg is effective and…
- Trial name
- NCT00286208
- Testing
- Mifepristone, misoprostol
- Where
- 9 sites in Moldova, Tunisia and 1 more
- Volunteers
- 1,443 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Cutaneous Lupus Erythematosus
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in disease activity will also be evaluated.
- Trial name
- NCT01470313
- Testing
- PD-0360324
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 28 people
- Sponsor
- Pfizer
Hypercholesterolemia
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
Primary Objective: Study the effect of mild or moderate hepatic impairment on the pharmacokinetics of alirocumab SAR236553 (REGN727).
- Trial name
- NCT01670734
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- 2 sites in France, Moldova
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sanofi
Rheumatoid Arthritis
Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching…
- Trial name
- NCT01668641
- Testing
- GLPG0634
- Where
- 19 sites in Hungary, Moldova and 2 more
- Volunteers
- 91 people
- Sponsor
- Lakefront Biotherapeutics NV
Heart Failure
Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease.
- Trial name
- NCT01265524
- Testing
- CLP
- Where
- 3 sites in Armenia, Georgia and 1 more
- Volunteers
- 113 people
- Sponsor
- Sorbent Therapeutics